Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats by unknown
ARTICLE
Differences in metabolic and mitogenic signalling of insulin
glargine and insulin aspart B10 in rats
N. Tennagels & S. Welte & M. Hofmann & P. Brenk & R. Schmidt & U. Werner
Received: 20 December 2012 /Accepted: 5 April 2013 /Published online: 8 May 2013
# Springer-Verlag Berlin Heidelberg 2013
Abstract
Aims/hypothesis In vitro, insulin glargine (A21Gly,B31Arg,
B32Arg human insulin) has an insulin receptor (IR) profile
similar to that of human insulin, but a slightly higher affinity
for the IGF-1 receptor (IGF1R). Insulin aspart B10 (B10Asp
human insulin) (AspB10), the only insulin analogue with prov-
en carcinogenic activity, has a greater affinity for IGF1R and
IR, and a prolonged IR occupancy time. The pharmacological
and signalling profile of therapeutic and suprapharmacological
doses of glargine were analysed in different tissues of rats, and
compared with human insulin and AspB10.
Methods Male Wistar rats were injected s.c. with human
insulin or insulin analogue at doses of 1 to 200 U/kg, and
the effects on blood glucose and the phosphorylation status
of IR, IGF1R, Akt and extracellular signal-regulated protein
kinase 1/2 in muscle, fat, liver and heart samples were
investigated.
Results Glargine, AspB10 and human insulin lowered blood
glucose, with the onset of action delayed with glargine.
Glargine treatment resulted in phosphorylation levels of IR
and Akt that were comparable with those achieved with
human insulin, although delayed in time in some tissues.
AspB10 treatment resulted in at least twofold higher phos-
phorylation levels and significantly longer duration of IR
and Akt phosphorylation in most tissues. None of the insulin
treatments resulted in detectable IGF1R phosphorylation in
muscle or heart tissue, whereas intravenous injection of
IGF-1 increased IGF1R phosphorylation.
Conclusions/interpretation The IR signalling pattern of
AspB10 in vivo is distinctly different from that of human
insulin and insulin glargine, and might challenge the notion
that activation of IGF1R plays a role in the observed carci-
nogenic effect of AspB10.
Keywords Akt . Asp[B10] insulin . Human insulin . IGF-1
receptor . Insulin glargine . Insulin receptor . Receptor
phosphorylation
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Insulin analogues in the treatment of patients with type 1 or
type 2 diabetes have been shown to be more efficient,
reproducible and convenient than regular insulin [1]. Due
to either sequence or secondary structural modifications,
analogues may differ from insulin with respect to metabolic
potency, stability, or onset and duration of action. Although
these changes were introduced to alter the time–action pro-
file of the respective insulin analogues, they may also lead
to an altered activation profile of the insulin receptor (IR)
and (or) IGF-1 receptor (IGF1R) signalling pathways, and
may change metabolic or mitogenic responses [2]. A careful
investigation of acute and long-term effects of insulin ana-
logues has been a major research focus.
The insulin analogue insulin aspart B10 (B10Asp human
insulin) (AspB10) was withdrawn from clinical development
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due to a higher incidence of breast cancer in rats [3]. AspB10
differs from human insulin by the substitution of histidine by
aspartate in position 10 of the B chain. In vitro, AspB10
displays higher affinity towards the IR and IGF1R, a
prolonged occupancy time at the IR and a higher proliferation
rate in mammalian cell lines. Although the mechanism by
which AspB10 exerts its mitogenic effect is not clear, it is still
contended that the analogue’s greater affinity to the IGF1R
might be at least in part responsible [4–7]. This has led to the
general belief that insulin analogues with increased IGF1R
affinity in vitro might per se exert an increased growth-
promoting activity in vivo.
However, in vitro studies cannot be directly applied to the
in vivo situation. First, the affinity of the endogenous ligand
IGF-1 for IGF1R is at least 100-fold greater than that of
insulin or insulin analogues. Thus, IGF-1 competes with
insulin for IGF1R occupation. Second, in vitro studies use
supraphysiological (nanomolar) concentrations vs
picomolar concentrations in vivo. Third, the plasma and
tissue concentration and distribution of insulin analogues
are different in vivo than in vitro. Fourth, insulin analogues
undergo biotransformation in vivo, necessitating analysis of
the active metabolites.
Insulin glargine (A21Gly,B31Arg,B32Arg human insu-
lin) is a long-acting human insulin analogue with an activity
profile very closely mimicking the natural physiological
profile of basal endogenous insulin secretion. Glargine dif-
fers from human insulin by substitution of asparagine by
glycine in position 21 of the A chain and by carboxy-
terminal extension of the B chain by two arginine residues.
These changes cause a shift in the isoelectric point from pH
5.4 to 6.7. Following s.c. administration as a clear solution
of pH 4, insulin glargine precipitates at the injection site
because of its low solubility at physiological pH levels. The
prolonged blood glucose-lowering activity of insulin
glargine may result from the subsequent slow dissolution
of the microprecipitate on the basis of a low dissociation
rate. The dissolution process is followed by rapid proteolytic
degradation of parent glargine, leading to soluble metabo-
lites as demonstrated in metabolism studies in humans, rats
and dogs [8–10]. The two main metabolites of insulin
glargine, M1 ([GlyA21]insulin) and M2 ([GlyA21,des-
ThrB30]insulin) are formed by the sequential removal of
the two arginines from the carboxy-terminus of the B chain
and additional deamination of threonine in position B30. In
plasma, the principal circulating compound is the metabolite
M1, the exposure of which increases as the dose of admin-
istered insulin glargine increases [11].
Insulin glargine has an in vitro IR signalling and meta-
bolic profile comparable to that of human insulin, but dis-
plays a slightly greater IGF1R affinity in vitro [4, 5, 7].
However, in 2 year carcinogenicity studies, no difference
was observed in the incidence of mammary tumours in mice
and rats compared with controls or animals treated with
NPH insulin [12], a finding that can be attributed to the
pharmacodynamic effect of M1, which has in vitro meta-
bolic and mitogenic profiles comparable with human insulin
[7].
The aim of this study was to analyse the time–action
profile of glargine in responsive tissues of rats with respect
to pharmacological and signalling variables and to compare
that profile to those of human insulin and AspB10, using
therapeutic as well as suprapharmacological doses. We also
investigated the effect of human insulin, glargine and
AspB10 on the phosphorylation of IGF1R and compared it
with the effect of IGF-1.
Methods
Animals
Male Wistar rats (HsdCpb:WU) were obtained from Charles
River, Sulzfeld, Germany. The animals were housed in
Macrolon cages (1,400 cm2; Ehret, Emmendingen,
Germany) on virtually dust-free wood granulate bedding,
enriched with nestling material, chow stick and hide tubes
(n=3–4 per cage). Animal housing conditions were
standardised (22±2°C, 55%±10% relative humidity, light
cycle from 06:00 to 18:00 hours) and a standard rodent
pellet diet (R/M-H 1534; ssniff Spezialdiäten, Soest,
Germany) was given until study start. Studies were
performed with rats at 8 to 10 weeks of age, after
acclimatisation for at least 1 week. Free access to tap water
was maintained at all times. The animals were randomised
to five to six rats per group and deprived of food 2 h before
the start of an experiment.
Injections
All injection solutions were freshly prepared. To achieve
final doses, regular human insulin and AspB10 were
dissolved in 0.9% (wt/vol.) saline, while glargine was
dissolved in a solution matching the glargine placebo at
pH 4. All test drugs and placebo were administered as a
single subcutaneous injection.
Study 1 In the first study, rats (n=5–6) were injected s.c.
with 1 U/kg (6 nmol/kg) of human insulin, glargine,
AspB10 or 0.9% saline (control group). Blood samples for
glucose and insulin analyses were taken at time point 0 and
at various time points up to 120 min after the injection.
Blood glucose was determined enzymatically from 5 μl of
tail tip whole blood haemolysed with 250 μl haemolysate
(haemolysis reagent H, Glucose Hexokinase Fluid 5+1;
Hengler Analytik, Steinbach, Germany). Quantification
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was with a Gluco-quant Glucose/HK kit (Roche
Diagnostics, Penzberg, Germany) using a Beckman
Coulter AU640 (Beckman Coulter, Krefeld, Germany) or a
Roche/Hi tachi 912 Chemis t ry Analyzer (Roche
Diagnostics, Mannheim, Germany). Serum insulin was de-
termined by human insulin immunoassay (ELISA 10-1113-
01; Mercodia, Uppsala, Sweden) unless otherwise stated.
The amount of insulin glargine, M1 and M2 in plasma was
determined by immunoaffinity extraction followed by liquid
chromatography–tandem mass spectrometry as described by
Bolli et al [11]. Samples of skeletal (calf) muscle, liver,
abdominal adipose tissue and heart were removed at the
same time points for analysis of IR, Akt (also known as
protein kinase B) and extracellular signal-regulated protein
kinase (ERK)1/2 phosphorylation.
Study 2 In a second study, rats (n=5) were injected s.c. with
12.5, 50 or 200 U/kg human insulin, glargine or AspB10 to
determine whether these high doses led to an increase in
IGF1R phosphorylation. Samples of calf muscle, liver, ab-
dominal adipose tissue and heart were removed after
60 min. As a control intended to demonstrate an IGF-1
effect on IGF1R downstream signalling, rats were injected
s.c. with 6 nmol/kg or i.v. with 6 or 136 nmol/kg des[1-3]
IGF-1, and calf muscle and heart samples were taken 60 min
after the s.c. injection or 5 min after the i.v. injection. All
tissue samples were subsequently analysed for IR, IGF1R
and Akt phosphorylation. Des[1-3]IGF-1 is a truncated var-
iant, which is more potent than human IGF-1 due to reduced
binding to IGF-binding proteins [13].
Study 3 In a third study, the effects on IR and IGF1R
phosphorylation in mammary tissue were examined in 74-
week-old female Sprague–Dawley rats (Charles River). The
rats (n=3–4) were injected s.c. with 12.5 U/kg human
insulin, glargine, AspB10 or saline, and mammary tissue
was removed at time 0 and 60 min. Other rats (n=3–4) were
injected intravenously with 1 mg/kg des[1-3]IGF, with skel-
etal muscle and heart samples being removed after 5 min.
Analyses
The phosphorylation of receptor and signalling molecules
was assessed by western blot analysis as described by Baus
et al [14]. After immunoprecipitation using antibodies di-
rected against the beta-subunit of the IR or IGF1R (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), proteins were
separated on SDS-PAGE gels (4–12% (wt/vol.) resolving
gel; Invitrogen, Carlsbad, CA, USA), transferred to
polyvinylidene difluoride membranes (Roche Applied
Science, Germany) and blocked (Roti-Block; Carl Roth,
Germany) for 1 h. Membranes were incubated overnight at
4°C with primary antibody directed against phosphotyrosine
(Millipore, Germany), IR or IGF1R. Membranes were
washed in TRIS-buffered saline + 0.1% (vol./vol.) Tween
20 and incubated with the appropriate secondary horserad-
ish peroxidase-conjugated antibody (Santa Cruz).
Immunoreactive bands were visualised with LumiLight
(Roche) and detected with a chemiluminescence detection
system (Lumi-Imager; Boehringer, Mannheim, Germany).
Phospho-Akt was determined using a phospho-Akt ELISA
kit (Life Technologies, Grand Island, NY, USA).
Study approval and statistical analysis
The animal studies were approved by the local Ethics
Committee and were conducted in accordance with the
Principles of Laboratory Care. All data are presented as
means±SEM. Statistical analysis was by one-way ANOVA
followed by Dunnett’s test, and was performed with a sta-
tistics analysis software (Prism; Graph Pad Software, San
Diego, CA USA).
Results
Effects on blood glucose and plasma insulin
After injection of 1 U/kg human insulin or AspB10, blood
glucose levels started to decline immediately, reaching min-
imum values of 4.3±0.1 mmol/l and 3.6±0.2 mmol/l after
30 and 60 min, respectively. Starting baseline values were
similar at 5.9 and 6.1 mmol/l (Fig. 1a). The glucose-
lowering action of 1 U/kg glargine was initially delayed
by 30 min but glucose levels reached a similar level of 4.1
±0.2 mmol/l after 90 min. However, the AUC was smaller
with glargine than with human insulin or AspB10, indicat-
ing a prolonged glucose-lowering action of this insulin
analogue. With higher doses, blood glucose was lowered
to the same extent by human insulin and insulin analogues,
reaching 28 to 41% of baseline without significant
hypoglycaemia (data not shown).
As in humans, glargine was effectively and rapidly
metabolised in rats. At 1 h after the injection of 1 U/kg
glargine, 90% of total insulin was identified as the M1 metab-
olite (1,407 pmol/l), whereas the parent compound was barely
detectable and the M2 metabolite was below the level of
quantification (Fig. 1b). The M1 metabolite also accounted
for 91% (5,122 pmol/l) and 76% (22, 969 pmol/l) of glargine
in plasma after injection of 12.5 and 200 U/kg glargine, where
the total insulin glargine concentration including metabolites
was 5,600 and 30,100 pmol/l, respectively (electronic supple-
mentary material [ESM] Fig. 1). However, even with a
suprapharmacological dose of 200 U/kg, the relative propor-
tion of glargine parent compound (18%, 5,288 pmol/l) and
M2 (6%, 1,826 pmol/l) remained low.
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Phosphorylation of the IR and signalling molecules
The time course of IR phosphorylation in skeletal muscle,
liver and fat tissue was examined following s.c. injection of
1 U/kg human insulin, glargine or AspB10. In muscle, the
time to peak phosphorylation with human insulin and
AspB10 was reached after 15 min, whereas with glargine
it was delayed until 30 min (Fig. 2a). AspB10 treatment
resulted in at least twofold higher peak phosphorylation
levels and a significantly longer duration of IR phos-
phorylation than treatment with human insulin. Peak
phosphorylation with glargine was lower than with
AspB10, but greater than with human insulin; the dura-
tion was also longer than with human insulin. In liver,
the time to peak phosphorylation was the same for all
three insulins (Fig. 2b). Only AspB10 showed greater
phosphorylation and a longer duration than human in-
sulin. In fat tissue, the time to peak phosphorylation
was later and peak phosphorylation was greater with
human insulin than with glargine or AspB10, while
the duration of phosphorylation was longer with
glargine (Fig. 2c).
Subcutaneous injection of 1 U/kg glargine resulted in peak
Akt phosphorylation comparable with that of 1 U/kg of
human insulin in skeletal muscle, liver and fat tissue
(Fig. 3). Time to peak phosphorylation was delayed in muscle
and fat tissue, but not in liver. AspB10 induced significantly
greater peak phosphorylation in muscle and liver, and also
prolonged the duration of Akt phosphorylation in skeletal
muscle. None of the insulins significantly increased ERK1/2
phosphorylation in any tissue examined (data not shown).
The effect of increasing suprapharmacological doses of
human insulin, glargine and AspB10 on IR and Akt phos-
phorylation in muscle was examined 60 min after s.c. injec-
tion, at a time when similar glucose-lowering effects were
observed with each insulin. Each insulin increased IR and
Akt phosphorylation, with no significant difference between
them detectable (Fig. 4). Comparable results were observed
in heart (data not shown).
Phosphorylation of IGF1R It was of interest to determine
whether the injection of high doses of human insulin,
AspB10 or glargine led to an increase in IGF1R phosphor-
ylation in skeletal muscle. As a control to demonstrate an
IGF-1 effect on IGF1R and downstream signalling, des[1-3]
IGF-1 was injected and the phosphorylation of IGF1R, IR
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Fig. 1 (a) Time course of blood glucose following s.c. injection of
1 U/kg human insulin (triangles), glargine (circles) or AspB10
(squares) in 8- to 10-week-old male Wistar rats. (b) Time course of
plasma glargine (white circles), metabolite M1 (diamonds) and total
serum immunoreactive insulin (crosses) concentrations after s.c. injec-
tion of 1 U/kg glargine in rats as above (a). Metabolite M2 was below
the lower limit of quantification. Values are mean±SEM (n=4); *p<
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Fig. 2 (a) Time course of IR phosphorylation in muscle, (b) liver and
(c) fat following s.c. injection of 1 U/kg human insulin (HI, triangles),
glargine (circles) or AspB10 (squares) in 8- to 10-week-old male
Wistar rats. Values are mean±SEM (n=5); *p<0.05, **p<0.01 and
***p<0.001 vs human insulin. PY, phosphotyrosine
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6 nmol/kg had no effect on any phosphorylation, whereas
i.v. injection of 6 or 136 nmol/kg increased IGF1R and Akt
phosphorylation in a dose-dependent manner, but had no
effect on IR phosphorylation. In contrast, s.c. injection of
increasing doses of human insulin, glargine or AspB10 had
no effect on muscle IGF1R phosphorylation after 60 min at
any dose (Fig. 6). The slight increase in the tyrosine phos-
phorylation signal observed at very high doses may have
been due to contaminating phospho-IR in the immunopre-
cipitate. Similar results were observed in heart (data not
shown). To show whether i.v. delivery of insulin analogues
resulted in IGF1R phosphorylation in muscle, 1 U/kg of
each analogue was injected, and IR and IGF1R phosphory-
lation was investigated after 5 min (ESM Fig. 2). Whereas
significant phosphorylation of the IR was detected, no
IGF1R phosphorylation was measurable with any insulin.
Total insulin levels after i.v. injection reached 14,844±
1,101 pmol/l. The majority of the insulin present in plasma
was the M1 metabolite (84%, 9,350 pmol/l), followed by
M2 (10%, 1,140 pmol/l) and parent glargine (6%,
652 pmol/l), indicating rapid metabolism in plasma.
Phosphorylation of IR and IGF1R in mammary tissue IGF1R
phosphorylation in mammary tissue was not significantly in-
creased when 74-week-old female rats were injected s.c. with
12.5 U/kg human insulin, glargine or AspB10 (Fig. 7). The
increased phosphorylation detected after AspB10 injection
mainly resulted from the presence of phospho-IR in the
IGF1R immunoprecipitate. Only AspB10 significantly in-
creased IR phosphorylation. Intravenous injection of 1 mg/kg
des[1-3]IGF-1 increased IGF1R phosphorylation 16-fold but
had no significant effect on IR phosphorylation.
Discussion
Given that patients with diabetes often require life-long
insulin treatment, it is essential to examine all steps in the
action of an insulin analogue in vitro and in vivo, to exclude
unwanted effects like growth-promoting activities [15].
Malignant cell growth is often associated with aberrant
signalling of both IR isoforms (IR-A and IR-B) and
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Fig. 3 (a) Time course of Akt phosphorylation in skeletal muscle, (b)
liver and (c) fat following s.c. injection of 1 U/kg human insulin
(triangles), glargine (circles) and AspB10 (squares) in 8- to 10-week-
old male Wistar rats. Values are mean±SEM (n=5); *p<0.05, **p<


































































































































































Fig. 4 (a–c) Muscle IR and (d–f) Akt phosphorylation 60 min after
s.c. injection of (a, d) 12.5, (b, e) 50 or (c, f) 200 U/kg human insulin
(HI), glargine or AspB10 in 8- to 10-week-old male Wistar rats. Values
are mean±SEM (n=5); *p<0.05, **p<0.01 and ***p<0.001 vs
control
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range of intracellular signals for metabolism, cell growth and
proliferation [16]. Their relative abundance affects intracellu-
lar signalling and has important consequences for tissue-
specific responses to insulin, IGFs and insulin analogues
[17, 18]. In addition, it has been demonstrated that
overexpression of IR and IGF1R in human breast carcinomas
allows insulin and IGF-1 hybrid receptors to form. These
hybrid receptors become tyrosine autophosphorylated when
breast cancer cells are exposed to IGF-1, but not to insulin,
and also mediate growth in response to IGF-1 [19–22].
As cancer cells have aberrant IR and IGF1R signalling
patterns, it is important to understand how insulin analogues
affect normal and cancerous cells, as this has implications
for diabetes, cancer and cancer treatment. It is generally
believed that insulin analogues with a higher affinity than
human insulin for IGF1R in vitro have greater mitogenic
activity in vivo. This belief is based on AspB10, the only
insulin analogue with proven carcinogenicity in rats [3].
Insulin glargine is also thought to have greater mitogenic
activity in vivo, based on its slightly higher affinity for
IGF1R in vitro, but unlike AspB10, glargine does not have
greater affinity for the IR or a prolonged occupancy time at
the IR [4, 5, 7].
It is, however, difficult to predict results in vivo on the
basis of in vitro data [23], and in vitro studies do not
conclusively support IGFR activation as the mechanism of
increased mitogenic activity. The mitogenic action of insulin
glargine is increased in certain cell lines with high IGFR:IR
ratios [6, 7, 24–28], but other cell lines with high IGFR:IR















































































































Fig. 5 (a) Western blot analysis of the phosphorylation of IGF1R, IR
and Akt at 60 min after the s.c. injection of 6 nmol/kg, or at 5 min after
the i.v. injection of 6 or 136 nmol/kg des[1-3]IGF-1 in 8- to 10-week-
old male Wistar rats. Quantification of (b) IGF1R, (c) IR and (d) Akt.


















Fig. 6 Western blots of muscle IGF1R phosphorylation 60 min after
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Fig. 7 (a) Western blot analysis of the phosphorylation of IR and
IGF1R in mammary tissue at 60 min after s.c. injection of saline or
12.5 U/kg human insulin (HI), glargine or AspB10, or at 5 min after i.v.
injection of 1 mg/kg des[1-3]IGF-1 in 74-week-old female Sprague–
Dawley rats (n=4). (b) Quantification of IGF1R and (c) IR phosphor-
ylation. Values are mean±SEM (n=3); **p<0.01 vs control. IP, im-
munoprecipitate; PY, phosphotyrosine
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increased proliferation [4, 5, 7, 24, 25, 29–34]. Moreover,
some cell lines respond to AspB10, but not to other ana-
logues with increased proliferation [35], while cell lines that
do not have a greater affinity for IGFR have also been reported
to show increased proliferation upon exposure to other insulin
analogues currently used in therapy [27, 28, 36].
One way of examining mitogenic activity in vivo is to
directly determine tumour formation after chronic treatment
with insulin and (or) insulin analogues. AspB10 was with-
drawn from clinical development due to a higher incidence
of breast cancer in rats after 12 months [3]. In contrast,
insulin glargine did not induce a higher incidence of mam-
mary tumours in lifetime carcinogenic studies in female rats
and mice [37], confirming that this basal insulin analogue is
unlikely to pose a cancer risk in humans. Moreover, in a
mouse model prone to tumour formation, Nagel et al [38]
demonstrated that tumour formation did not increase with
insulin glargine vs NPH insulin treatment after 18 months.
The balance of evidence indicates that no commercially
available insulin analogue has carcinogenic effects in the
human clinical setting [10]. The approach presented here
was to examine the time course of phosphorylation of the IR
and IGF1R, and the effects on downstream signalling mol-
ecules of insulin and insulin analogues in different tissues in
rats. Previous studies have been performed in mice [39, 40].
The one rat study that has been reported to date used
suprapharmacological doses and only investigated down-
stream signalling [17].
Blood glucose levels dropped immediately after the in-
jection of human insulin or AspB10, with no difference
between the two insulins. In contrast, glucose lowering
was delayed with insulin glargine, as expected for a long-
acting insulin analogue, where the mode of action involves
precipitation and subsequent slow release from the tissue
depot [41]. As in humans [11, 42], the lowering of blood
glucose could be correlated to the biotransformation of
insulin glargine into the M1 metabolite, which lacks the
di-arginine residues [8]. Glargine parent and M2 were not
detectable. Consequently M1, and not glargine itself, is the
primary driver of the pharmacodynamic effect and the long-
acting time–action profile observed with insulin glargine
treatment [11, 42]. The proteases responsible for this activity
appear to be independent of the species investigated [43].
M1 is the major active metabolite even at a dose of
200 U/kg, suggesting that the protease system involved
has a high capacity. However, at this high dose, glargine
can be found in the circulation, indicating that saturation of
the system can occur.
Peak IR and Akt phosphorylation levels induced by
insulin glargine were generally comparable with those
achieved with human insulin, although in some tissues the
effects of insulin glargine were delayed and (or) prolonged
in time. Similar differences have been described by Agouni
et al [39], possibly reflecting differences in pharmacokinetic
and/or pharmacodynamic properties across tissues. The
comparable peak phosphorylation of insulin glargine vs
human insulin reflects the comparable activity of M1 vs
human insulin and supports the conclusion that insulin
glargine behaves like human insulin in terms of signalling.
In contrast, IR and Akt phosphorylation was increased and
prolonged with AspB10, most strikingly in muscle and liver.
These results are compatible with the greater affinity of the
IR for AspB10 and with the prolonged signalling of the IR
when exposed to AspB10 in vitro [6, 7]. Interestingly, at
higher doses (12.5 and 200 U/kg), the differences in peak
phosphorylation of the IR and Akt observed between
AspB10, glargine and insulin were no longer detectable, ap-
parently demonstrating the saturation of peak phosphorylation
under these high-dose conditions. Hvid et al have reported that
100 U/kg s.c. resulted in comparable peak phosphorylation of
Akt over 150 min [17, 18]. Consequently, a therapeutic dose
of 1 U/kg seems to reflect differences in the affinity of
AspB10, insulin and insulin glargine to the IR in vitro [7].
The presence and activation of the IGF1R in muscle,
heart and mammary tissue was demonstrated by intravenous
injection of a high dose of IGF-1 (136 nmol/kg), whereas
6 nmol/kg IGF-1 injected s.c. was unable to generate de-
tectable receptor autophosphorylation. A similar result was
reported in mouse heart muscle, where the injection of
136 nmol/kg IGF-1 i.v. resulted in strong phosphorylation
of the receptor, whereas no signal could be detected after i.v.
injection of a therapeutic 4 nmol/kg dose [44]. The tight
control of IGF1R phosphorylation was also demonstrated by
Hvid et al [17], who reported that s.c. injection of a
supraphysiological dose (600 nmol/kg) of IGF-1 in rats
increased Akt phosphorylation in liver, colon and mammary
gland of Sprague–Dawley rats. In agreement with a relative-
ly poor response to IGF-1, Lee et al reported that Akt and
ERK phosphorylation occurred in mouse mammary gland
tissue only after a large bolus tail vein injection [45].
Although it has been demonstrated that the large bolus can
result in the majority of the IGF-1 being in circulation [46],
it should be noted that part of the dose could be bound to
IGF-binding proteins, which would limit the free concentra-
tion and explain a reduced response [45]. In any case, we
used des[1-3]IGF-1, which lacks the N-terminal tripeptide
Gly-Pro-Glu and has increased potency due to reduced
binding to most of the IGF-binding proteins [13]. Thus i.v.
injection of des[1-3]IGF-1 should directly allow characteri-
sation of the tissue IGF1R response.
Neither human insulin nor insulin analogues generated
significant IGF1R signals in these tissues at s.c. doses up to
200 U/kg. The same holds true when the analogues were
administered i.v. and the phosphorylation pattern was stud-
ied after 5 min. Importantly, animals that received an insulin
glargine injection of 200 U/kg showed a free serum insulin
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M1 level of 22 nmol/l, which is 30-fold below the reported
affinity of M1 to the IGF1R [7]. In the same study, the
measured concentrations of parent glargine and M2 were
5 nmol/l and 2 nmol/l, respectively, with the total insulin
concentration reaching about 30 nmol/l. Assuming similar
concentrations were achieved with AspB10 at a dose of
200 U/kg, the lack of IGF1R phosphorylation would be
remarkable, since this concentration should be able to in-
crease IGF-1 phosphorylation in vitro [7]. The tendency for
a high dose of AspB10 to show an increase in the tyrosine
phosphorylation signal of the immunoprecipitate may be a
reflection of phosphorylated IR contamination due to co-
precipitation of IR by the antibody used in these studies. It
may also reflect IR subunits precipitated as IR and/or IGFR
hybrids. Hybrid receptors have been detected in a number of
tissues including human skeletal and heart muscle, and
adipose tissue [6, 47]. Glargine itself might have a higher
affinity for hybrid receptors in vitro [6, 47], but M1 is like
human insulin and thus no signal was observed in vivo.
In summary, AspB10 treatment resulted in a blood glu-
cose profile comparable to that of insulin. The phosphory-
lation of signalling molecules was increased and (or)
prolonged in most tissues, which resembles in vitro find-
ings. The glycaemic action of insulin glargine was (slightly)
retarded compared with insulin. Insulin glargine is rapidly
and effectively metabolised to M1 under therapeutic and
high-dose conditions, and the phosphorylation of signalling
molecules in tissues was generally comparable to that of
insulin, but retarded in time in some tissues. IGF1R phosphor-
ylation could not be detected in several tissues upon exposure
to insulin glargine or AspB10, even at high dose and different
routes of administration. We conclude that in rats AspB10 has
a different IR signalling profile to that of insulin and insulin
glargine, and that the slightly elevated IGF1R activity of
AspB10 in vitro did not translate into IGF1R phosphorylation
in vivo. Consequently, we hypothesise that the greater mito-
genic effect of AspB10 is most likely to be based on its altered
IR profile in vivo. It is therefore tempting to speculate that the
greater mitogenic effects of insulin and insulin analogues are
solely based on the growth-promoting activity of the IR itself,
and that IGF1R activation by insulin analogues may be less
relevant under therapeutic conditions than previously
discussed.
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